Insiders · AVBP

AVBP insider transactions

ArriVent BioPharma Inc. (AVBP) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for AVBP

• 2h
  SEC Form 4 filed by Director Parsey Merdad

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 2h
  SEC Form 4 filed by Director Peterson Kristine

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 2h
  SEC Form 4 filed by Director Hohneker John

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 2h
  SEC Form 4 filed by Director Nolet Chris

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 138d
  SEC Form 4 filed by Chief Operating Officer Lachapelle Robin

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 138d
  SEC Form 4 filed by President of R&D Lutzker Stuart

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 138d
  SEC Form 4 filed by Chief Financial Officer Kung Winston

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 138d
  SEC Form 4 filed by General Counsel Kastenmayer James Paul

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 138d
  SEC Form 4 filed by President and CEO Yao Zhengbin

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 139d
  Large owner Hillhouse Investment Management, Ltd. sold $12,983,320 worth of shares (555,555 units at $23.37) (SEC Form 4)

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 342d
  Chief Operating Officer Lachapelle Robin exercised 11,153 shares at a strike of $2.28, increasing direct ownership by 9% to 135,736 units (SEC Form 4)

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 367d
  SEC Form 4 filed by Director Parsey Merdad

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 367d
  SEC Form 4 filed by Director Peterson Kristine

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 367d
  SEC Form 4 filed by Director Hohneker John

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 367d
  SEC Form 4 filed by Director Nolet Chris

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 419d
  SEC Form 4 filed by Director Parsey Merdad

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 419d
  SEC Form 3 filed by new insider Parsey Merdad

  3 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 493d
  SEC Form 4 filed by President and CEO Yao Zhengbin

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 493d
  SEC Form 4 filed by President of R&D Lutzker Stuart

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 493d
  SEC Form 4 filed by Chief Operating Officer Lachapelle Robin

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 493d
  SEC Form 4 filed by Chief Financial Officer Kung Winston

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 493d
  SEC Form 4 filed by General Counsel Kastenmayer James Paul

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 637d
  Chief Operating Officer Lachapelle Robin exercised 27,566 shares at a strike of $3.28, increasing direct ownership by 28% to 124,583 units (SEC Form 4)

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 763d
  SEC Form 4 filed by Hohneker John

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 763d
  SEC Form 3 filed by new insider Hohneker John

  3 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 790d
  SEC Form 3 filed by new insider Peterson Kristine

  3 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 790d
  SEC Form 4 filed by Peterson Kristine

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)